VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CLBTCellebrite DI Ltd.
$13.76$3.4B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCLBTCash Flow

Cellebrite DI Ltd. (CLBT) Cash Flow Statement

7Y historyFree accessUpdated daily

Free cash flow generation remains volatile, peaking at a 60.8% margin in 2025Q4, while the firm continues to deploy capital for M&A, including a $147.5 million net acquisition outflow in the same period.

CLBT Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Cash from Operations167.97M168.96M132.17M102.06M20.58M36.05M66.51M16.13M
Operating CF Margin %-35.52%32.94%31.39%7.6%14.64%34.12%9.39%
Operating CF Growth %124.28%27.83%29.51%395.98%-42.92%-45.79%312.26%-
Net Income71.86M78.33M-283.01M-81.1M120.81M71.4M5.78M-1.88M
Depreciation & Amortization16.24M11.87M10.61M10.01M9.19M7.01M5.88M4.08M
Stock-Based Compensation24.12M030.57M19M13.71M6.48M7.27M12.76M
Deferred Taxes-289K75K-4.01M5.13M-2.39M-1.64M-2.82M-1.67M
Other Non-Cash Items18.12M36.67M335.96M110.5M-117.92M-67.87M689K131K
Working Capital Changes37.91M42.02M42.05M38.52M-2.82M20.68M49.71M2.71M
Change in Receivables14.94M-15.78M-5.83M2.27M-12.88M-1.96M-19.73M-12.22M
Change in Inventory1.79M1.63M982K243K-3.68M-1.8M-693K794K
Change in Payables4.25M9.19M2.75M3.69M-5.47M4.24M-1.43M974K
Cash from Investing-155.32M-268.25M-149.47M-22.54M-91.23M45.23M-6.45M-46.72M
Capital Expenditures-20.99M-13.22M-8.57M-5.23M-6.9M-5.11M-6.18M-6.21M
CapEx % of Revenue4.23%2.78%2.14%1.61%2.55%2.08%3.17%3.61%
Acquisitions-162.73M-147.46M-2.75M00-20M-15.05M0
Investments--------
Other Investing11.61M861K-2.04M-2.69M-2.19M-3M0-40.51M
Cash from Financing29.53M29.64M20.65M21.77M13.97M-68.4M-8.59M75.54M
Debt Issued (Net)4.58M4.58M000000
Equity Issued (Net)24.94M25.05M0000-85K100.4M
Dividends Paid00000-100M-10M-25M
Share Repurchases000000-85K-808K
Other Financing0020.65M21.77M13.97M31.6M1.49M141K
Net Change in Cash43.21M-67.2M2.14M101.87M-58.33M12.13M52.16M44.88M
Free Cash Flow154.04M155.73M121.56M94.14M11.49M27.94M60.33M9.92M
FCF Margin %31.03%32.74%30.3%28.96%4.25%11.35%30.95%5.77%
FCF Growth %16.54%28.11%29.13%719.18%-58.87%-53.69%507.91%-
FCF per Share0.610.620.580.500.060.170.320.05
FCF Conversion (FCF/Net Income)2.14x2.16x-0.47x-1.26x0.17x0.50x11.50x-8.60x
Interest Paid00000000
Taxes Paid4.69M07.71M10.05M9.05M8.16M2.91M3M

Key Metrics

Growth RegimeDecelerating
ProfitabilityModerate
Balance SheetHealthy
Cash FlowImproving
Top Statement Risk

Geopolitical and regulatory exposure

Earnings Quality Masked by Accruals

As reported in financial statements, Cellebrite's operating cash flow frequently decouples from net income, with the OCF/NI ratio reaching as high as 3.87 in 2025Q4, suggesting that reported earnings may not fully capture the underlying cash-generative capacity of the firm's subscription-based business model.

The significant divergence between net income and operating cash flow appears driven by substantial non-cash adjustments and working capital fluctuations. Investors should monitor whether this gap reflects genuine operational efficiency or merely the timing of deferred revenue recognition inherent in the transition to multi-year software contracts.

FCF Margin Expansion Amid Normalization

Based on recent quarterly filings, Cellebrite has demonstrated a volatile but generally positive free cash flow trajectory, with FCF margins peaking at 60.8% in 2025Q4, indicating that the company is successfully converting its high-margin software revenue into tangible liquidity despite periodic R&D-related cash outflows.

The variability in FCF margins suggests that while the core business is highly cash-generative, it remains sensitive to the timing of large-scale government contract renewals and associated working capital swings. The ability to maintain positive FCF even during periods of net losses highlights the resilience of the underlying subscription revenue stream.

Cyclical Working Capital Efficiency Trends

According to historical data, Cellebrite experiences significant quarterly swings in working capital, with a notable $42.7 million inflow in 2025Q4 followed by an $8.8 million outflow in 2026Q1, reflecting the seasonal nature of public sector procurement cycles and the timing of large-scale software maintenance billings.

These fluctuations suggest that the company's cash position is heavily influenced by the timing of government budget cycles rather than purely operational performance. Analysts should interpret these shifts as a reflection of the firm's reliance on large, lumpy contract renewals rather than a fundamental deterioration in collection efficiency.

Strategic Capital Allocation and M&A

As evidenced by the $147.5 million net acquisition outflow in 2025Q4, Cellebrite is actively deploying its cash reserves to consolidate the forensic software market, a strategy that appears aimed at expanding its technological moat beyond its traditional extraction-focused hardware roots.

The company's willingness to utilize its cash balance for inorganic growth suggests management is prioritizing market share and capability expansion over immediate cash accumulation. Investors should monitor whether these acquisitions provide the expected synergies or if they introduce integration risks that could weigh on future operating margins.

CLBT — Frequently Asked Questions

Quick answers to the most common questions about buying CLBT stock.

How much cash does Cellebrite DI Ltd. (CLBT) generate from operations?

Cellebrite DI Ltd. (CLBT) generated $169.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Cellebrite DI Ltd.'s free cash flow?

Cellebrite DI Ltd. (CLBT) generated $155.7M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Cellebrite DI Ltd.'s capital expenditure (CapEx)?

Cellebrite DI Ltd. (CLBT) spent $13.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.